Edwards Lifesciences (NYSE:EW) Upgraded by Wolfe Research to “Outperform” Rating

Wolfe Research upgraded shares of Edwards Lifesciences (NYSE:EW) from a peer perform rating to an outperform rating in a research note released on Wednesday, MarketBeat.com reports. The brokerage currently has $92.00 price target on the medical research company’s stock.

Several other equities research analysts have also recently weighed in on the company. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Stock Performance

Shares of EW opened at $81.46 on Wednesday. The company has a 50-day simple moving average of $81.78 and a two-hundred day simple moving average of $81.72. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $46.97 billion, a PE ratio of 44.52, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. The firm’s revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the transaction, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 61,718 shares of company stock valued at $5,236,281. 1.29% of the stock is currently owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently bought and sold shares of the company. J. Derek Lewis & Associates Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $323,000. Rockefeller Capital Management L.P. increased its position in shares of Edwards Lifesciences by 2.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 36,707 shares of the medical research company’s stock valued at $3,129,000 after acquiring an additional 922 shares in the last quarter. World Investment Advisors increased its position in shares of Edwards Lifesciences by 10.7% during the fourth quarter. World Investment Advisors now owns 39,986 shares of the medical research company’s stock valued at $3,409,000 after acquiring an additional 3,877 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Edwards Lifesciences by 20.7% in the 4th quarter. Corient Private Wealth LLC now owns 100,051 shares of the medical research company’s stock worth $8,547,000 after acquiring an additional 17,144 shares during the last quarter. Finally, Hsbc Holdings PLC raised its holdings in Edwards Lifesciences by 0.7% in the 4th quarter. Hsbc Holdings PLC now owns 2,148,974 shares of the medical research company’s stock worth $183,188,000 after acquiring an additional 15,577 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.